HC Wainwright Reiterates Buy Rating for Citius Pharmaceuticals (NASDAQ:CTXR)

Citius Pharmaceuticals (NASDAQ:CTXR)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They currently have a $4.00 price objective on the stock.

Separately, EF Hutton Acquisition Co. I upgraded Citius Pharmaceuticals to a “strong-buy” rating in a research note on Monday, July 15th.

Citius Pharmaceuticals Trading Up 9.2 %

Shares of CTXR opened at $0.45 on Tuesday. The company’s 50-day moving average price is $0.45 and its 200 day moving average price is $0.61. Citius Pharmaceuticals has a 12-month low of $0.31 and a 12-month high of $1.07. The firm has a market cap of $81.18 million, a P/E ratio of -1.87 and a beta of 1.66.

Citius Pharmaceuticals (NASDAQ:CTXR) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). Equities research analysts forecast that Citius Pharmaceuticals will post -0.21 earnings per share for the current year.

Institutional Trading of Citius Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of CTXR. Point72 DIFC Ltd purchased a new stake in Citius Pharmaceuticals during the 2nd quarter worth about $29,000. BNP Paribas Financial Markets increased its position in shares of Citius Pharmaceuticals by 88.5% in the 1st quarter. BNP Paribas Financial Markets now owns 69,615 shares of the company’s stock valued at $62,000 after purchasing an additional 32,686 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new position in Citius Pharmaceuticals in the second quarter valued at $69,000. Arkadios Wealth Advisors increased its holdings in shares of Citius Pharmaceuticals by 50.0% in the 2nd quarter. Arkadios Wealth Advisors now owns 150,000 shares of the company’s stock valued at $88,000 after acquiring an additional 50,000 shares during the last quarter. Finally, Wealth Advisory Solutions LLC raised its position in shares of Citius Pharmaceuticals by 33.1% during the 3rd quarter. Wealth Advisory Solutions LLC now owns 201,000 shares of the company’s stock worth $101,000 after acquiring an additional 50,000 shares in the last quarter. 16.88% of the stock is currently owned by hedge funds and other institutional investors.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.